Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AmeriSource/Bergen

Executive Summary

Federal Trade Commission requests additional information regarding proposed merger of AmeriSource and Bergen Brunswig, companies state May 7. The merger, announced March 19, would create the largest drug wholesaler (1"The Pink Sheet" March 26, p. 5)

You may also be interested in...



AmeriSource/Bergen FTC review

"The Federal Trade Commission's second request" on the proposed merger between AmeriSource and Bergen "is broad in nature and covers nearly all facets of the business of both companies," AmeriSource tells employees in a Q&A on the merger. In May, the two companies reported that FTC had requested additional information regarding the transaction, which would create the largest drug wholesaler (1"The Pink Sheet" May 14, In Brief)

AmeriSource/Bergen FTC review

"The Federal Trade Commission's second request" on the proposed merger between AmeriSource and Bergen "is broad in nature and covers nearly all facets of the business of both companies," AmeriSource tells employees in a Q&A on the merger. In May, the two companies reported that FTC had requested additional information regarding the transaction, which would create the largest drug wholesaler (1"The Pink Sheet" May 14, In Brief)

AmeriSource Expects Post-Merger Market Share Of 33% To Pass FTC Review

AmeriSource and Bergen Brunswig predict the Federal Trade Commission will accept their combined 33% market share in the drug wholesaling sector without initiating an antitrust challenge.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel